Giant cell arteritis with visual loss following zoledronic acid infusion

Authors

  • Samy Metyas,

    1. Department of Medicine – Rheumatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Search for more papers by this author
  • Makary Ibrahim,

    1. Covina Arthritis, Covina, California, USA
    Search for more papers by this author
  • John Solyman,

    1. Covina Arthritis, Covina, California, USA
    Search for more papers by this author
  • Karen C. Yeter,

    1. Department of Medicine – Rheumatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Search for more papers by this author
  • Daniel G. Arkfeld

    Corresponding author
    1. Department of Medicine – Rheumatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    • Correspondence: Daniel G. Arkfeld, MD, Associate Professor of Clinical Medicine, University of Southern California, Keck School of Medicine, Department of Medicine – Rheumatology, 2011 Zonal Ave, HMR 711, Los Angeles, CA 90033, USA. Email: arkfeld@usc.edu

    Search for more papers by this author

Abstract

Zoledronic acid is used in the treatment of osteoporosis. Giant cell artertitis may lead to vision loss. We report a case in which vision loss occurred after zoledronic acid infusion.

Ancillary